Xtandi Better, Cheaper than Zytiga for Treatment of mCRPC, Study Suggests
News
Treating chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients with Xtandi (enzalutamide) leads to better survival outcomes and lower healthcare costs than Zytiga (abiraterone acetate), a study suggests. The findings were ... Read more